Logo image of BBIO

BRIDGEBIO PHARMA INC (BBIO) Stock Fundamental Analysis

NASDAQ:BBIO - US10806X1028 - Common Stock

49.08 USD
-1.15 (-2.29%)
Last: 8/22/2025, 8:00:02 PM
48.9 USD
-0.18 (-0.37%)
After Hours: 8/22/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BBIO. BBIO was compared to 549 industry peers in the Biotechnology industry. BBIO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, BBIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BBIO has reported negative net income.
In the past year BBIO has reported a negative cash flow from operations.
BBIO had negative earnings in each of the past 5 years.
BBIO had a negative operating cash flow in each of the past 5 years.
BBIO Yearly Net Income VS EBIT VS OCF VS FCFBBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

BBIO has a worse Return On Assets (-71.88%) than 63.57% of its industry peers.
Industry RankSector Rank
ROA -71.88%
ROE N/A
ROIC N/A
ROA(3y)-84.41%
ROA(5y)-74.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBIO Yearly ROA, ROE, ROICBBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

Looking at the Gross Margin, with a value of 96.19%, BBIO belongs to the top of the industry, outperforming 95.26% of the companies in the same industry.
In the last couple of years the Gross Margin of BBIO has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5Y0.92%
BBIO Yearly Profit, Operating, Gross MarginsBBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

BBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
BBIO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BBIO has been increased compared to 5 years ago.
Compared to 1 year ago, BBIO has an improved debt to assets ratio.
BBIO Yearly Shares OutstandingBBIO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BBIO Yearly Total Debt VS Total AssetsBBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -3.41, we must say that BBIO is in the distress zone and has some risk of bankruptcy.
BBIO's Altman-Z score of -3.41 is in line compared to the rest of the industry. BBIO outperforms 46.99% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.41
ROIC/WACCN/A
WACC9.46%
BBIO Yearly LT Debt VS Equity VS FCFBBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

BBIO has a Current Ratio of 5.19. This indicates that BBIO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.19, BBIO is in line with its industry, outperforming 55.56% of the companies in the same industry.
A Quick Ratio of 5.08 indicates that BBIO has no problem at all paying its short term obligations.
BBIO has a Quick ratio (5.08) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.19
Quick Ratio 5.08
BBIO Yearly Current Assets VS Current LiabilitesBBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for BBIO have decreased strongly by -64.64% in the last year.
The Revenue has been growing slightly by 7.62% in the past year.
Measured over the past years, BBIO shows a very strong growth in Revenue. The Revenue has been growing by 40.48% on average per year.
EPS 1Y (TTM)-64.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-143.59%
Revenue 1Y (TTM)7.62%
Revenue growth 3Y47.1%
Revenue growth 5Y40.48%
Sales Q2Q%4999.86%

3.2 Future

BBIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.74% yearly.
BBIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.96% yearly.
EPS Next Y-4.05%
EPS Next 2Y14.97%
EPS Next 3Y25.93%
EPS Next 5Y27.74%
Revenue Next Year104.46%
Revenue Next 2Y77.62%
Revenue Next 3Y77.63%
Revenue Next 5Y64.96%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BBIO Yearly Revenue VS EstimatesBBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
BBIO Yearly EPS VS EstimatesBBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBIO Price Earnings VS Forward Price EarningsBBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBIO Per share dataBBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

BBIO's earnings are expected to grow with 25.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.97%
EPS Next 3Y25.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (8/22/2025, 8:00:02 PM)

After market: 48.9 -0.18 (-0.37%)

49.08

-1.15 (-2.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners86.19%
Inst Owner Change0.58%
Ins Owners4.34%
Ins Owner Change-5.81%
Market Cap9.32B
Analysts84.44
Price Target64.06 (30.52%)
Short Float %11.33%
Short Ratio6.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.94%
Min EPS beat(2)-10.44%
Max EPS beat(2)6.56%
EPS beat(4)1
Avg EPS beat(4)-8.86%
Min EPS beat(4)-21.38%
Max EPS beat(4)6.56%
EPS beat(8)3
Avg EPS beat(8)8.72%
EPS beat(12)4
Avg EPS beat(12)4.03%
EPS beat(16)5
Avg EPS beat(16)6.44%
Revenue beat(2)2
Avg Revenue beat(2)51.6%
Min Revenue beat(2)18.58%
Max Revenue beat(2)84.61%
Revenue beat(4)3
Avg Revenue beat(4)35.03%
Min Revenue beat(4)-28.8%
Max Revenue beat(4)84.61%
Revenue beat(8)4
Avg Revenue beat(8)175.18%
Revenue beat(12)4
Avg Revenue beat(12)96.08%
Revenue beat(16)5
Avg Revenue beat(16)81.87%
PT rev (1m)4.36%
PT rev (3m)5.99%
EPS NQ rev (1m)-0.45%
EPS NQ rev (3m)13.25%
EPS NY rev (1m)0%
EPS NY rev (3m)0.46%
Revenue NQ rev (1m)19.1%
Revenue NQ rev (3m)129.12%
Revenue NY rev (1m)-0.49%
Revenue NY rev (3m)9.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 39.52
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.33
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)-3.52
FCFYN/A
OCF(TTM)-3.45
OCFYN/A
SpS1.24
BVpS-9.42
TBVpS-9.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.88%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.19%
FCFM N/A
ROA(3y)-84.41%
ROA(5y)-74.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5Y0.92%
F-Score3
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 211.73%
Cap/Sales 4.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.19
Quick Ratio 5.08
Altman-Z -3.41
F-Score3
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)86.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)8.73%
Cap/Sales(5y)27.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-64.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-143.59%
EPS Next Y-4.05%
EPS Next 2Y14.97%
EPS Next 3Y25.93%
EPS Next 5Y27.74%
Revenue 1Y (TTM)7.62%
Revenue growth 3Y47.1%
Revenue growth 5Y40.48%
Sales Q2Q%4999.86%
Revenue Next Year104.46%
Revenue Next 2Y77.62%
Revenue Next 3Y77.63%
Revenue Next 5Y64.96%
EBIT growth 1Y-28.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.08%
EBIT Next 3Y30.23%
EBIT Next 5Y16.28%
FCF growth 1Y-36.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.92%
OCF growth 3YN/A
OCF growth 5YN/A